Clinical Trials Arena on MSN
Pfizer and Astellas’ Xtandi improves OS as combination therapy
While there was a positive trend in the monotherapy cohort, there was no statistical improvement in OS.
At its November 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use recommended granting marketing authorization in the EU for Enzalutamide Accordpharma ...
Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...
Breakthrough for prostate cancer patients as NHS now offers life-extending drug - The new medication is suitable for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results